For inventions involving biological materials – novel microorganisms, cell lines, plasmids, hybridomas, genetically engineered organisms, or other living matter that can’t be fully described in words – patent applicants face a disclosure problem unique to biotechnology. Written description alone often cannot enable a skilled person to reproduce a biological invention, since the same nucleotide or amino acid sequence can behave differently depending on subtle, unrecorded variables. Patent systems solve this through two coordinated but distinct mechanisms: deposit of biological material under the Budapest Treaty and sequence listings that disclose genetic sequence data in a standardized digital format. Getting the coordination between these two right – timing, cross-referencing and consistency – is a frequent source of costly errors in biotech patent prosecution.
Why Two Separate Systems Exist
It’s a common misconception that a sequence listing alone is sufficient disclosure for a biological invention, or conversely, that a deposit alone covers sequence disclosure requirements. They serve different purposes:
- Sequence listings disclose the informational content of nucleic acid and amino acid sequences in a machine-readable, standardized text format, allowing examiners, competitors and the public to search, compare and analyze genetic sequences claimed or referenced in the application.
- Biological deposits under the Budapest Treaty satisfy the enablement requirement when the biological material itself – not just its sequence information – is necessary to practice the invention and is not readily available or reproducible from a written description alone (e.g., a specific hybridoma cell line, a mutant microbial strain, or a plant variety).
Many applications require both: a sequence listing describing the genetic content and a deposit of the actual physical material, cross-referenced to each other within the specification.
The Budapest Treaty Framework
What It Is
The Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (1977, administered by WIPO) allows an applicant to make a single deposit at one International Depositary Authority (IDA) and have that deposit recognized by all contracting states, rather than requiring separate deposits in every jurisdiction where patent protection is sought.
Key International Depositary Authorities
Commonly used IDAs include:
- ATCC (American Type Culture Collection) – United States
- DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) – Germany
- NCIMB (National Collection of Industrial, Food and Marine Bacteria) – United Kingdom
- CGMCC (China General Microbiological Culture Collection Center) – China
- NITE-NPMD (National Institute of Technology and Evaluation) – Japan
- CNCM (Collection Nationale de Cultures de Microorganismes, Institut Pasteur) – France
Each IDA has its own submission procedures, viability testing protocols and fee schedules, but all issue a standardized receipt confirming deposit that is recognized across contracting states.
What Qualifies as a “Microorganism” Under the Treaty
The term is interpreted broadly by patent offices and IDAs to include not just bacteria and fungi, but also:
- Cell lines (including hybridomas)
- Plasmids and other vectors
- Viruses and bacteriophages
- Algae and protozoa
- Plant and animal tissue cultures, in many jurisdictions
- Seeds, in some cases, though these may also fall under separate plant variety protection regimes
Timing Requirements – The Most Common Pitfall
Timing is where deposit-related errors most often derail prosecution or, worse, invalidate a patent. General principles across major jurisdictions:
| Jurisdiction | Deadline for Deposit |
| United States (USPTO) | On or before the effective filing date; if not, must be made before filing and referenced, or within a limited window with a showing of good cause – waiting is high-risk |
| European Patent Office (EPO) | No later than the filing date of the application |
| Japan (JPO) | Before filing, or within a specified short grace period with justification |
| China (CNIPA) | Before filing, with the deposit receipt due within a specified period after filing |
Practical rule of thumb: deposit before filing, never after. Relying on a post-filing grace period is a fallback for emergencies, not a filing strategy, since requirements and available leniency vary by jurisdiction and some offices apply them strictly.
Priority Claims and Deposit Timing
When claiming priority from an earlier application (e.g., under the Paris Convention or via a PCT filing), the deposit generally must have been made on or before the priority filing date to be validly relied upon in later-filed applications claiming that priority – not merely before the later filing date. Applicants who deposit between the priority date and the later national/regional filing risk having the deposit disregarded for the purposes of the earlier priority claim.
Required Elements of the Deposit Disclosure in the Specification
A properly coordinated specification referencing a Budapest Treaty deposit typically must include:
- Name and address of the depositary institution (the IDA)
- Date of deposit
- Accession number assigned by the IDA
- Identification of any relevant taxonomic designation of the deposited material
- A statement confirming all restrictions on public availability will be irrevocably removed upon grant of the patent (required by most offices, including USPTO 37 CFR ยง 1.808 and EPO Rule 31 EPC)
- Confirmation that the deposit will be maintained for the required duration – generally the longer of 30 years from deposit, 5 years after the last request for a sample, or the enforceable life of the patent
Missing any of these elements, or including them inconsistently between the specification and the actual deposit receipt, is a frequent basis for office actions requesting correction – and in the worst case, can affect enablement if the discrepancy isn’t resolved before grant.
Sequence Listings: The Other Half of the Disclosure
The Shift to WIPO Standard ST.26
As of July 1, 2022, the WIPO Standard ST.26 replaced the older ST.25 format as the required XML-based standard for sequence listings across major patent offices (USPTO, EPO and PCT applications filed with WIPO as receiving office). Key practical implications:
- Sequence listings must be filed as XML files generated using WIPO Sequence software (the free tool WIPO provides) or equivalent compliant software – plain text ST.25-format listings are no longer accepted for applications filed after the transition date
- ST.26 introduced more granular qualifiers, stricter formatting for branched/circular sequences and updated requirements for annotating features
- Applications with international/PCT filing dates before the transition generally still follow ST.25 conventions for any national phase continuations tied to that filing date; coordination with counsel on which standard applies to a given filing lineage is essential
What Triggers a Sequence Listing Requirement
A sequence listing is required whenever the application discloses:
- Nucleotide sequences of 10 or more bases (thresholds vary slightly by jurisdiction)
- Amino acid sequences of 4 or more specifically defined residues
- Sequences referenced in the claims, even if only by SEQ ID NO. reference rather than spelled out in the claim text itself
Consistency Between Sequence Listing and Specification
Examiners routinely check that:
- Every SEQ ID NO. referenced in the specification and claims actually appears in the sequence listing
- Sequence listing content matches sequences described or claimed in the body of the application (discrepancies between a sequence described in prose and the corresponding listing entry are a common, easily preventable error)
- Feature annotations (e.g., coding regions, promoters, mutation sites) in the listing align with how those features are discussed substantively in the specification
Coordinating Deposits and Sequence Listings: Where the Two Intersect
For many biotech inventions – a genetically modified microbial strain producing a therapeutic protein, for example – both a deposit and a sequence listing are required and they must be internally consistent with each other:
- If the specification states the deposited strain contains a plasmid expressing a sequence identified as SEQ ID NO. 3, that sequence must actually be present in and correctly represented as isolated from, the deposited material – examiners and, later, litigation experts can and do request sample analysis to verify this
- Any amendments to the sequence listing after filing (e.g., correcting an error) must not introduce new matter and should be cross-checked against the deposit to confirm the correction doesn’t create inconsistency with the physical sample already on deposit
- When multiple deposits are referenced (e.g., a parent strain and a derivative), the specification must clearly distinguish accession numbers and correlate each to its corresponding sequence data
Common Coordination Errors and Their Consequences
| Error | Risk |
| Deposit made after the priority filing date | Loss of ability to rely on the deposit for priority purposes; potential enablement rejection |
| Accession number omitted or incorrect in the specification | Office action requiring correction; possible delay in examination |
| Sequence listing filed in outdated format (ST.25 post-transition) | Formal rejection requiring refiling in ST.26 XML |
| SEQ ID NO. referenced in claims but missing from listing | Objection under enablement/written description; claim may be held indefinite |
| Deposit accessibility restrictions not released as required at grant | Patent validity risk – enablement requires public accessibility |
| Deposit not maintained for required statutory period | Risk to enforceability if a sample becomes unavailable during patent term |
| Mismatch between deposited strain and sequence listing content | Can undermine both enablement and written description support; discoverable in litigation |
Key Takeaway
Deposits and sequence listings are not interchangeable disclosure mechanisms and treating them as an afterthought – or handling them separately without cross-checking consistency – is one of the most preventable sources of prosecution delay and validity risk in biotechnology patenting. The safest practice is to treat deposit logistics and sequence listing preparation as parallel work streams that must be finalized and cross-verified before the earliest priority filing, not as post-filing administrative cleanup.